Q1 2024 Earnings Forecast for Oncternal Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:ONCT)

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) – Analysts at HC Wainwright lifted their Q1 2024 earnings per share (EPS) estimates for Oncternal Therapeutics in a research report issued on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.30) per share for the quarter, up from their previous estimate of ($3.52). HC Wainwright currently has a “Buy” rating and a $28.00 target price on the stock. The consensus estimate for Oncternal Therapeutics’ current full-year earnings is ($12.03) per share. HC Wainwright also issued estimates for Oncternal Therapeutics’ Q2 2024 earnings at ($3.42) EPS, Q3 2024 earnings at ($3.63) EPS, Q4 2024 earnings at ($3.68) EPS and FY2024 earnings at ($14.04) EPS.

Oncternal Therapeutics (NASDAQ:ONCT) last released its quarterly earnings data on Thursday, March 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The company had revenue of $0.30 million during the quarter, compared to analysts’ expectations of $0.17 million. Oncternal Therapeutics had a negative return on equity of 95.87% and a negative net margin of 5,029.17%. During the same quarter in the prior year, the firm posted ($4.00) EPS.

Separately, StockNews.com began coverage on Oncternal Therapeutics in a report on Wednesday. They issued a “hold” rating on the stock.

Oncternal Therapeutics Trading Up 0.2 %

ONCT opened at $8.71 on Thursday. The company has a market cap of $23.42 million, a P/E ratio of -0.64 and a beta of 1.26. The business’s 50-day moving average price is $8.92 and its 200-day moving average price is $8.11. Oncternal Therapeutics has a 12 month low of $5.57 and a 12 month high of $13.14.

Institutional Trading of Oncternal Therapeutics

Several large investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its position in Oncternal Therapeutics by 13.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 189,634 shares of the company’s stock valued at $211,000 after acquiring an additional 21,785 shares in the last quarter. Mirabella Financial Services LLP bought a new stake in Oncternal Therapeutics during the 1st quarter valued at approximately $38,000. Prudential Financial Inc. bought a new stake in Oncternal Therapeutics during the 2nd quarter valued at approximately $32,000. Renaissance Technologies LLC boosted its position in Oncternal Therapeutics by 12.5% during the 2nd quarter. Renaissance Technologies LLC now owns 287,000 shares of the company’s stock valued at $99,000 after acquiring an additional 31,900 shares in the last quarter. Finally, Virtu Financial LLC bought a new stake in Oncternal Therapeutics during the 2nd quarter valued at approximately $48,000. 16.05% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Oncternal Therapeutics news, Director Robert James Wills bought 3,086 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The shares were bought at an average cost of $8.96 per share, with a total value of $27,650.56. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $89,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have acquired 10,714 shares of company stock valued at $92,736 over the last ninety days. 8.00% of the stock is owned by insiders.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.